Business
MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at
About this update from Natera, Inc.
[{"type":"text","content":"MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting. By integrating methylation signatures (epigenetic signatures) into its whole-genome platform, MyOme is moving beyond traditional DNA sequencing to resolve the complex cases that currently contribute to an average five-year diagnostic delay for rare disease patients[1,2]. Recent meta-analyses confirm that a genome-first approach significantly increases diagnostic yield and clinical utility over legacy exome methods, providing the necessary foundation for MyOme's multi-omic innovations.[3]\n \n \n \n \n \n \n \nNatera Launches Zenith™ powered by MyOmeIn a major step toward expanding patient access, MyOme is highlighting its strategic partnership with Natera (NASDAQ: NTRA) to launch Zenith™ powered by MyOme. Zenith is a premium exome and genome testing solution that brings MyOme's innovative genome-first platform to Natera's industry-leading clinical network.The Zenith portfolio is available for commercial orders through Natera, bringing Zenith genomics to healthcare providers across the United States, leveraging its extensive electronic medical records (EMR) integration footprint, robust clinical support system and unparalleled experience in high-complexity genomics.\"Rare disease patients and their families endure lengthy and costly diagnostic journeys that often delay care and escalate emotional and financial strain,\" said Meredith Reichert, Ph.D., senior vice president of commercial and general manager of rare disease at Natera. \"By combining MyOme's innovation with Natera's nationwide presence and clinical expertise, Zenith has the potential to transform rare disease diagnostics and provide definitive answers to more families.\"The Methylation AdvantageTraditional genetic testing identifies changes in the DNA sequence, but requires separate testing to evaluate epigenetic modifications that dictate how genes are expressed. MyOme's new multi-omic approach leverages long-read sequencing to simultaneously analyze DNA sequence and methylation patterns to look for specific disease-related \"epigenetic signatures.\"At launch, MyOme will perform targeted confirmation for select conditions, with a strat...